{"slug":"adc","as_of":"2026-10-22","verified_at":"2026-10-22","languages":{"zh":{"title":"台灣 ADC 公司與管線總表","summary":[{"text":"截至2026年10月22日，本表收錄8家台灣公司的ADC管線或區域授權產品，並逐列標明公司角色與來源日期。","source_urls":["https://clinicaltrials.gov/api/v2/studies/NCT06480240","https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed","https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/","https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","https://mopsov.twse.com.tw/nas/STR/414720260715M001.pdf","https://mopsov.twse.com.tw/nas/STR/411420260312M001.pdf","https://www.oepgroup.com/upload/media/investors/2025%20Q4%20%E5%8F%8B%E8%8F%AF%E7%94%9F%E6%8A%80%E6%B3%95%E8%AA%AA%E6%9C%83.pdf"]},{"text":"所列浩鼎與醣聯管線已進入臨床，藥華藥與中裕所列ADC仍在臨床前；台新藥與台康共同開發同一個TSY-110／EG12043。","source_urls":["https://clinicaltrials.gov/api/v2/studies/NCT06480240","https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed","https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/","https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","https://mopsov.twse.com.tw/nas/STR/414720260715M001.pdf","https://mopsov.twse.com.tw/nas/STR/411420260312M001.pdf","https://www.oepgroup.com/upload/media/investors/2025%20Q4%20%E5%8F%8B%E8%8F%AF%E7%94%9F%E6%8A%80%E6%B3%95%E8%AA%AA%E6%9C%83.pdf"]}],"undisclosed":"本表是已核對公司與所選管線的名單，並非全產業清冊；未核實的試驗開始、結果與核准日期均不填補。"},"en":{"title":"Taiwan ADC Companies and Pipelines","summary":[{"text":"As of October 22, 2026, this table includes ADC programs or regionally licensed products at 8 Taiwan companies, with roles and source dates retained.","source_urls":["https://clinicaltrials.gov/api/v2/studies/NCT06480240","https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed","https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/","https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","https://mopsov.twse.com.tw/nas/STR/414720260715M001.pdf","https://mopsov.twse.com.tw/nas/STR/411420260312M001.pdf","https://www.oepgroup.com/upload/media/investors/2025%20Q4%20%E5%8F%8B%E8%8F%AF%E7%94%9F%E6%8A%80%E6%B3%95%E8%AA%AA%E6%9C%83.pdf"]},{"text":"The selected OBI Pharma and GlycoNex programs have entered clinical trials, while the selected PharmaEssentia and TaiMed ADCs remain preclinical; Formosa Pharmaceuticals and EirGenix co-develop the same TSY-110 / EG12043.","source_urls":["https://clinicaltrials.gov/api/v2/studies/NCT06480240","https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed","https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/","https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","https://mopsov.twse.com.tw/nas/STR/414720260715M001.pdf","https://mopsov.twse.com.tw/nas/STR/411420260312M001.pdf","https://www.oepgroup.com/upload/media/investors/2025%20Q4%20%E5%8F%8B%E8%8F%AF%E7%94%9F%E6%8A%80%E6%B3%95%E8%AA%AA%E6%9C%83.pdf"]}],"undisclosed":"This is a verified selection, not an industry census. Unverified trial starts, results and approval dates are not filled in."}},"companies":[{"company":"浩鼎","company_en":"OBI Pharma","ticker":"4174","product":"OBI-992","product_en":"OBI-992","indication":"晚期實體腫瘤","indication_en":"Advanced solid tumors","stage":"第 1/2 期；進行中但不再收案","stage_en":"Phase 1/2; active, not recruiting","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"ACTIVE_NOT_RECRUITING","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"台灣浩鼎生技股份有限公司","catalyst":null,"date_basis":"登錄最後公開更新2025-08-08；於2026-10-22重新讀取，不將查核日當成狀態更新日。"},{"company":"醣聯","company_en":"GlycoNex","ticker":"4168","product":"GNX1021（ADC）","product_en":"GNX1021 (ADC)","indication":"晚期實體腫瘤（一期試驗收案族群）","indication_en":"Advanced solid tumors (Phase 1 enrollment)","stage":"第 1 期；日本首位受試者已給藥","stage_en":"Phase 1; first patient dosed in Japan","as_of":"2026-08-03","source":"https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed","quote":"Phase 1 clinical trial of GNX1021","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"台灣醣聯生技醫藥股份有限公司","catalyst":{"text":"2026-08-03 公告日本一期首位受試者給藥。","text_en":"First patient dosing in Japan announced on August 3, 2026.","as_of":"2026-08-03","source":"https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed","quote":"first patient"}},{"company":"台新藥","company_en":"Formosa Pharmaceuticals","ticker":"6838","product":"TSY-110／EG12043（與台康共同開發）","product_en":"TSY-110 / EG12043 (co-developed with EirGenix)","indication":"HER2 陽性轉移性與早期乳癌","indication_en":"HER2-positive metastatic and early-stage breast cancer","stage":"歐洲臨床試驗申請（CTA）已提交","stage_en":"European clinical trial application submitted","as_of":"2026-08-28","source":"https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/","quote":"Clinical Trial Application (CTA)","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"台新藥股份有限公司","catalyst":null},{"company":"台康生技","company_en":"EirGenix","ticker":"6589","product":"EG12043／TSY-110（與台新藥共同開發）","product_en":"EG12043 / TSY-110 (co-developed with Formosa Pharmaceuticals)","indication":"HER2 陽性轉移性與早期乳癌","indication_en":"HER2-positive metastatic and early-stage breast cancer","stage":"共同開發案已提交歐洲 CTA","stage_en":"Co-developed program: European CTA submitted","as_of":"2026-08-28","source":"https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/","quote":"Clinical Trial Application (CTA)","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"台康生技股份有限公司","catalyst":null},{"company":"藥華藥","company_en":"PharmaEssentia","ticker":"6446","product":"ADC (novel target)（未揭露個別代號）","product_en":"ADC (novel target; individual code undisclosed)","indication":"實體腫瘤","indication_en":"Solid tumors","stage":"臨床前；IND-enabling","stage_en":"Preclinical; IND-enabling","as_of":"2026-08-25","source":"https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","quote":"IND ENABLING","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"藥華醫藥股份有限公司","catalyst":{"text":"公司計畫於2027年提出此ADC的IND，屬計畫，非已提交。","text_en":"The company plans an IND for this ADC in 2027; this is planned, not a submitted filing.","as_of":"2026-08-25","source":"https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","quote":"Planned IND in 2027"},"source_page":28,"date_basis":"公開法說檔日期2026-08-25；第28頁色條另以頁面影像核對，尚未進入一期。"},{"company":"中裕","company_en":"TaiMed Biologics","ticker":"4147","product":"TMB-HIV ADC","product_en":"TMB-HIV ADC","indication":"HIV 治療／治癒研究","indication_en":"HIV treatment / cure research","stage":"臨床前","stage_en":"Preclinical","as_of":"2026-07","source":"https://mopsov.twse.com.tw/nas/STR/414720260715M001.pdf","quote":"臨床前 Preclinical","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"中裕新藥股份有限公司","catalyst":null,"date_precision":"month","source_page":5,"date_basis":"簡報封面只標July2026，不以檔名臆測事件日。"},{"company":"健喬","company_en":"Synmosa Biopharma","ticker":"4114","product":"Tivdak（台灣代理與商業化權）","product_en":"Tivdak (Taiwan distribution and commercialization rights)","indication":"復發或轉移性子宮頸癌","indication_en":"Recurrent or metastatic cervical cancer","stage":"台灣已送件；公司角色為代理與商業化","stage_en":"Taiwan filing submitted; company role is commercialization","as_of":"2026-03-12","source":"https://mopsov.twse.com.tw/nas/STR/411420260312M001.pdf","quote":"台灣已送件","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"健喬信元醫藥生技股份有限公司","catalyst":null,"source_page":11},{"company":"友華","company_en":"Orient EuroPharma","ticker":"4120","product":"TE-1146（台灣、東協、紐澳代理經銷權）","product_en":"TE-1146 (Taiwan, ASEAN, Australia and New Zealand distribution rights)","indication":"多發性骨髓瘤","indication_en":"Multiple myeloma","stage":"臨床前開發；友華為區域授權夥伴","stage_en":"Preclinical development; regional licensee","as_of":"2026-10-22","source":"https://www.oepgroup.com/upload/media/investors/2025%20Q4%20%E5%8F%8B%E8%8F%AF%E7%94%9F%E6%8A%80%E6%B3%95%E8%AA%AA%E6%9C%83.pdf","quote":"臨床前開發階段","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"友華生技醫藥股份有限公司","catalyst":null,"source_page":16,"date_basis":"2025Q4營運成果簡報；本檔未提供確切發布日，as_of為查閱日。"}],"scope":{"not_exhaustive":true,"coverage":"Source-verified selection from existing Taiwan company profiles; one row per company, with one named program or service selected for that company.","stage_basis":"Stage is the statement in the cited source as of its stated date; an undated live page uses the access date. Development, trial authorization, recruitment and marketing authorization remain separate.","count_basis":"Company rows, not an industry-wide census or a count of independent drugs. Licensed products, original development and customer manufacturing are identified in product and stage fields."}}